Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 2/20 | 0.51 |
| ▸ | PLAU | P00749 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.49 |
| ▸ | ITGAV | P06756 | 6/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.49 |
| ▸ | MC4R | P32245 | 7/20 | 0.48 |
| ▸ | MC5R | P33032 | 7/20 | 0.48 |
| ▸ | MC3R | P41968 | 7/20 | 0.48 |
| ▸ | MC1R | Q01726 | 7/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.48 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12837665 | 1.00 | CTSG (0.51) | CTSGPLAUITGB3ITGAVITGB1 | |
| SCHEMBL11926071 | 0.94 | CTSG (0.55) | CTSGPLAUITGB3ITGAVITGB1 | |
| SCHEMBL14137295 | 0.92 | CTSG (0.54) | CTSGPLAUITGB3ITGAVITGB1 | |
| SCHEMBL13659869 | 0.92 | CTSG (0.54) | CTSGPLAUITGB3ITGAVITGB1 | |
| SCHEMBL22278847 | 0.92 | ITGB3 (0.52) | CTSGPLAUITGB3ITGAVITGB1 | |
| SCHEMBL13649571 | 0.92 | CTSG (0.50) | CTSGPLAUITGB3ITGAVITGB1 | |
| SCHEMBL22003475 | 0.91 | ITGB3 (0.55) | CTSGPLAUITGB3ITGAVITGB1 | |
| SCHEMBL10052602 | 0.91 | ITGB3 (0.55) | CTSGPLAUITGB3ITGAVITGB1 | |
| SCHEMBL16298655 | 0.91 | ITGB3 (0.55) | CTSGPLAUITGB3ITGAVITGB1 | |
| SCHEMBL9909400 | 0.91 | ITGB3 (0.55) | CTSGPLAUITGB3ITGAVITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404802-B2 | a targeting vector which binds to receptors associated with integrin receptors, angiogenesis; contrast agents; diagnosis of malignant diseases, heart diseases, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma | GE HEALTHCARE AS (NO) | 2013-03-26 | — | — | US | disclosed |
| US-7608243-B2 | RGD peptide sequence; labelled with fluorescein used as contrast agents in optical imaging in diagnosis of angiogenesis-related diseases; peptidic vector and the fluorescein dye are coupled; cyclic peptide forming disulife or monothioether bridge | GE HEALTHCARE AS (NO) | 2009-10-27 | — | — | US | disclosed |
| US-20070183977-A1 | Fluorescein-labelled peptides | AMERSHAM HEALTH AS (NO) | 2007-08-09 | — | — | US | disclosed |
| US-20070116646-A1 | Optical imaging of endometriosis | KLAVENESS JO | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070183977-A1 | Fluorescein-labelled peptides | FLT4, FLT1, KDR | CTSG 619/4885PLAU 882/4885ITGB3 468/4885 |
| US-20070116646-A1 | Optical imaging of endometriosis | LGALS3BP, SDF4, OGFRL1 | CTSG 2403/4885PLAU 1255/4885ITGB3 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.